31 results about "Friedelin" patented technology

The present invention discloses the composition, extraction process and use of total triterpene sapogenin extracted from bamboo. The triterpene sapogenin is extracted from stem, branch, leaf, root, shoot, etc. of bamboo as one kind of gramineous plant via supercritical CO2 fluid extraction process. The test via vanillin-perchloric acid colorimetry method and GC-MS method shows that the extractive has total triterpene sapogenin content of 10-90 %, friedelin content of 5-35 % and lupenone content of 1-10 %. The extractive as one mixture of five-cycle triterpene compounds (EZR2002) has excellent physiological and pharmacological activity of resisting free radical, resisting oxidation, resisting tumor, lowering blood pressure, etc. and may be used in medicine and health care article for preventing and treating cardiac and cerebral vascular diseases and resisting tumor and may be also used in cosmetics.

The invention relates to a medicine for treating asthma and a preparation method thereof. The medicine takes pentacyclic triterpenoid, particularly friedelin, corosolic acid or a mixture thereof and an optional second active ingredient as active ingredients for treating asthma, can obviously inhibit the attack of the asthma and inhibit the secretion of inflammatory factors, and has certain activity of inhibiting the contraction of tracheal smooth muscle, so that the medicine can be used for preventing and treating asthma.

The invention relates to a triterpene synthase of tripterygium wilfordii TwOSC3 protein and an encoding gene thereof. A recombinant expression vector with a Twosc3 gene is constructed by cloning cDNAof the Twosc3 gene onto a eukaryotic expression vector pYES2, and then the recombinant expression vector is shifted to yeast expression host bacteria, so as to acquire friedelin. A mutation research result shows that amino acid 482 encoded by the Twosc3 gene is a key site, and the yield of friedelin or amyrin can be increased or reduced; a gene gun mediated interference experiment shows that the interference of the Twosc3 gene has an obvious inhibiting effect on the synthesis of celastrol in tripterygium wilfordii; the TwOSC3 protein and the encoding gene thereof provided by the invention canbe used for biosynthesizing plant triterpenoids and cultivating high-quality tripterygium wilfordii.

The invention provides a pharmaceutical composition which comprises a pharmaceutical carrier and at least one compound selected from the group consisting of cobaltocene-octamethyl, stigmastan-3,5 -diene,galaxolide, benzyl salicylate, eucalyptol, and α-pinene. Also provided is a method of preparing a composition having antimicrobial activity comprising extracting a plant material in an organic solvent, contacting the extracted material to a chromatographic column, and eluting from the chromatographic column with a mobile polar phase to obtain a composition. The plant material is from Mammea Americana, Marchantaceae polymorpha, or Callistemon citrinus. Also provided is a method of inhibiting the growth of a mycobacterium, comprising administering a composition comprising a carrier and at least one compound selected from among cobaltocene-octamethyl, stigmastan, 3,5-diene, friedelin, galaxolide, benzyl salicylate, eucalyptol, and α-pinene.

The invention discloses a pouzolzia extract, a preparation method thereof, and an application thereof. According to the invention, for a first time, four compounds are separated and identified from subsiding swelling and pus removing effective parts of pouzolzia. A water extract prepared from pouzolzia and a chloroform or n-butyl alcohol extracted part thereof provide subsiding swelling and pus removing effects. The chloroform extracted part contains friedelin. The n-butyl alcohol extracted part contains kaempferol-7-O-alpha-L-pyran rhamnoside, quercetin-7-O-alpha-L-pyran rhamnoside, quercetin-3, and 7-O-alpha-L-2-pyran rhamnoside. The extract provided by the invention provides good subsiding swelling, pus removing, inflammation resisting, and pain relieving effects. The extract can be used for preparing subsiding swelling and pus removing medicines.

The invention provides a pharmaceutical composition which comprises a pharmaceutical carrier and at least one compound selected from the group consisting of cobaltocene-octamethyl, stigmastan-3,5-diene, galoxolide, benzyl salicylate, eucalyptol, and α-pinene. Also provided is a method of preparing a composition having antimicrobial activity comprising extracting a plant material in an organic solvent, contacting the extracted material to a chromatographic column, and eluting from the chromatographic column with a mobile polar phase to obtain a composition. The plant material is from Mammea Americana, Marchntia polymorpha, or Callistemon citrinus. Also provided is a method of inhibiting the growth of a mycobacterium, comprising administering a composition comprising a carrier and at least one compound selected from among cobaltocene-octamethyl, stigmastan, 3,5-diene, friedelin, galoxolide, benzyl salicylate, eucalyptol, and α-pinene.

A Tripterygium wilfordii triterpene synthase TwOSC1 protein and a coding gene thereof. cDNA of a TwOSC1 gene is cloned to eukaryotic expression vector pYES2, and a recombinant expression vector carrying the TwOSC1 gene is constructed and transformed into a yeast expression host, allowing triterpenoids such as friedelin and amyrins to be produced. Mutation research has shown that amino acids 486 and 502 in the code of the TwOSC1 gene are key sites able to increase or decrease production of friedelin or amyrins. Gene gun-mediated interference experimentation has shown that interference of the TwOSC1 gene has a marked inhibiting effect on the synthesis of celastrol in Tripterygium wilfordii, and further gene gun-mediated overexpression experimentation has shown that overexpression of the TwOSC1 gene can increase production of celastrol in Tripterygium wilfordii suspension cells. TwOSC1 protein and the coding gene therefor may be used in biosynthesis of plant triterpenoids, and in cultivating high-quality Tripterygium wilfordii.

The invention relates to the technical field of traditional Chinese medicine, and discloses monimopetalum Chinese extract with anti-inflammatory activity. The monimopetalum Chinese extract is an effective component formed by pristimerin, wilforol A, polpunonic acid, celastrol, tingenone, friedelin and other triterpene ingredients. A preparing method is characterized by including the steps that stems and leaves of the plant monimopetalum Chinese (Monimopetalum Chinese Rehd.) are used as raw materials and extracted with methyl alcohol, or ethyl alcohol or water-containing alcohol, an extracting solution is filtered and condensed to a small volume, a small amount of water is added to suspend the filtered and condensed extracting solution, then macroporous resin column chromatography is used, and 80-100% of an alcohol elution component is collected to obtain the total triterpene component. The preparing method is simple in process and reasonable in operation, and the extract has an obvious inhibiting effect on inflammatory mediators such as prostaglandin E2 and nitric oxide, has an inhibiting effect on swelling and exudation caused by acute inflammation and granulation hyperplasia caused by chronic inflammation in rat bodies and mice bodies and provides a theoretical and experimental basis for clinical medication of Monimopetalum Chinese for treating rheumatic arthritis.

The invention belongs to the technical field of medicine, and particularly relates to a medicinal composition for preventing vascular dementia and an application thereof. The medicinal composition comprises the following raw materials: Lycium barbarum polysaccharide component II, Lycium barbarum polysaccharide component VI, Astragalus polysaccharides component A2, ajugol A and friedelin-3beta-ol. The medicinal composition provided by the invention has a remarkably curative effect on preventing vascular dementia, and has stable quality control and is suitable for long-term administration of patients.

The invention belongs to the technical field of medicine, particularly relates to a medicinal composition for treating vascular dementia and application thereof. The medicinal composition is prepared from the following raw materials: lycium barbarum polysaccharide component III, lycium barbarum polysaccharide component I, astragalus polysaccharide component A3, ajugol A, phillyrin and friedelin-3beta-ol. The medicinal composition provided by the invention has distinct therapeutic effect on vascular dementia, has stable quality control, and is suitable for long-term administration of patients.